Aureus Asset Management, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Aureus Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$27.51 - $57.29 $4.63 Million - $9.64 Million	-168,343 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$40.86 - $57.65 $28,561 - $40,297	-699 Reduced 0.41%	168,343 $9.17 Million
Q3 2019 Nov 12, 2019	BUY	$37.38 - $49.47 $384,640 - $509,046	10,290 Added 6.48%	169,042 $7.05 Million
Q2 2019 Aug 14, 2019	SELL	$39.79 - $67.01 $11,937 - $20,103	-300 Reduced 0.19%	158,752 $6.95 Million
Q1 2019 May 13, 2019	SELL	$34.52 - $53.29 $99,417 - $153,475	-2,880 Reduced 1.78%	159,052 $8.19 Million
Q4 2018 Feb 13, 2019	SELL	$29.75 - $42.9 $204,918 - $295,495	-6,888 Reduced 4.08%	161,932 $5.99 Million
Q3 2018 Nov 14, 2018	BUY	$32.79 - $43.0 $859,098 - $1.13 Million	26,200 Added 18.37%	168,820 $6.34 Million
Q2 2018 Aug 13, 2018	BUY	$23.62 - $42.29 $159,198 - $285,034	6,740 Added 4.96%	142,620 $5.64 Million
Q1 2018 May 15, 2018	BUY	$22.49 - $34.56 $3.06 Million - $4.7 Million	135,880 New	135,880 $3.5 Million

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Aureus Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Aureus Asset Management, LLC with notifications on news.